{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:57:53Z","timestamp":1785542273388,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK114497"],"award-info":[{"award-number":["K23DK114497"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK109134"],"award-info":[{"award-number":["K23DK109134"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K23AG051679"],"award-info":[{"award-number":["K23AG051679"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s11606-019-05557-8","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T11:03:44Z","timestamp":1576494224000},"page":"1092-1101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Use of Potentially Nephrotoxic Medications by U.S. Adults with Chronic Kidney Disease: NHANES, 2011\u20132016"],"prefix":"10.1007","volume":"35","author":[{"given":"Shaheen","family":"Kurani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly Moore","family":"Jeffery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorg","family":"Thorsteinsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaTonya J.","family":"Hickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin F.","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Giblon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-3183","authenticated-orcid":false,"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"5557_CR1","unstructured":"CDC 2017 Pages. Accessed at US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation at https:\/\/www.cdc.gov\/kidneydisease\/pdf\/kidney_factsheet.pdf on January 10 2019."},{"issue":"2","key":"5557_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000335935","volume":"35","author":"DS Tuot","year":"2012","unstructured":"Tuot DS, Plantinga LC, Hsu C-y, Powe NR. Is awareness of chronic kidney disease associated with evidence-based guideline-concordant outcomes? American journal of nephrology. 2012;35(2):191\u20137.","journal-title":"American journal of nephrology."},{"issue":"3","key":"5557_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.ackd.2010.03.002","volume":"17","author":"LC Plantinga","year":"2010","unstructured":"Plantinga LC, Tuot DS, Powe NR. Awareness of chronic kidney disease among patients and providers. Advances in chronic kidney disease. 2010;17(3):225\u201336.","journal-title":"Advances in chronic kidney disease."},{"issue":"20","key":"5557_CR4","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/archinte.168.20.2268","volume":"168","author":"LC Plantinga","year":"2008","unstructured":"Plantinga LC, Boulware LE, Coresh J, Stevens LA, Miller ER, 3rd, Saran R, et al. Patient awareness of chronic kidney disease: trends and predictors. Arch Intern Med. 2008;168(20):2268\u201375.","journal-title":"Arch Intern Med."},{"key":"5557_CR5","unstructured":"CDC [Website]. 2014;Pages. Accessed at Centers for Disease Control and Prevention at https:\/\/nccd.cdc.gov\/ckd\/data.aspx on February 14 2019."},{"issue":"10159","key":"5557_CR6","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052\u201390.","journal-title":"Lancet."},{"key":"5557_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12882-015-0189-z","volume":"16","author":"SD Fraser","year":"2015","unstructured":"Fraser SD, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, et al. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. BMC Nephrol. 2015;16:193.","journal-title":"BMC Nephrol."},{"issue":"3 Suppl 2","key":"5557_CR8","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1053\/j.ajkd.2009.09.035","volume":"55","author":"LA Stevens","year":"2010","unstructured":"Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010;55(3 Suppl 2):S23\u201333.","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"5557_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/ki.2015.228","volume":"88","author":"M Tonelli","year":"2015","unstructured":"Tonelli M, Wiebe N, Guthrie B, James MT, Quan H, Fortin M, et al. Comorbidity as a driver of adverse outcomes in people with chronic kidney disease. Kidney Int. 2015;88(4):859\u201366.","journal-title":"Kidney Int."},{"issue":"7","key":"5557_CR10","first-page":"1085","volume":"13","author":"TN Lea-Henry","year":"2018","unstructured":"Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical pharmacokinetics in kidney disease. Fundamental Principles. 2018;13(7):1085\u201395.","journal-title":"Fundamental Principles."},{"issue":"5","key":"5557_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jama.2010.39","volume":"303","author":"BR Hemmelgarn","year":"2010","unstructured":"Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303(5):423\u20139.","journal-title":"JAMA."},{"issue":"1","key":"5557_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"KDIGO","year":"2013","unstructured":"KDIGO. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements. 2013;3(1):1\u2013150.","journal-title":"Kidney International Supplements."},{"key":"5557_CR13","doi-asserted-by":"crossref","unstructured":"Adverse drug effects in relation to renal function: Jick H: Am J Med 62: 514\u2013517, 1977. The American Journal of Medicine. 1977;62(4):A97.","DOI":"10.1016\/0002-9343(77)90406-5"},{"issue":"5","key":"5557_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/clpt.2009.135","volume":"86","author":"DC Brater","year":"2009","unstructured":"Brater DC. Drug dosing in patients with impaired renal function. Clin Pharmacol Ther. 2009;86(5):483\u20139.","journal-title":"Clin Pharmacol Ther."},{"key":"5557_CR15","volume-title":"Brookline","author":"S Brownlee","year":"2017","unstructured":"Brownlee S, Garber J. Medication overload: America\u2019s other drug problem. In: Institute L, ed. Brookline, MA: Lown Institute; 2017."},{"issue":"11","key":"5557_CR16","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.2215\/CJN.00580118","volume":"13","author":"CF Whittaker","year":"2018","unstructured":"Whittaker CF, Miklich MA, Patel RS, Fink JC. Medication safety principles and practice in CKD. Clinical Journal of the American Society of Nephrology. 2018;13(11):1738\u201346.","journal-title":"Clinical Journal of the American Society of Nephrology."},{"issue":"9","key":"5557_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med."},{"key":"5557_CR18","unstructured":"Micromedex\u00ae (electronic version). Greenwood Village, Colorado, USA: IBM Watson Health; 2019."},{"issue":"5","key":"5557_CR19","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1053\/j.ajkd.2010.05.024","volume":"56","author":"AB McCoy","year":"2010","unstructured":"McCoy AB, Waitman LR, Gadd CS, Danciu I, Smith JP, Lewis JB, et al. A computerized provider order entry intervention for medication safety during acute kidney injury: a quality improvement report. American Journal of Kidney Diseases. 2010;56(5):832\u201341.","journal-title":"American Journal of Kidney Diseases."},{"issue":"4","key":"5557_CR20","doi-asserted-by":"publisher","first-page":"856","DOI":"10.2215\/CJN.08110910","volume":"6","author":"BS Moffett","year":"2011","unstructured":"Moffett BS, Goldstein SL. Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children. Clinical Journal of the American Society of Nephrology. 2011;6(4):856\u201363.","journal-title":"Clinical Journal of the American Society of Nephrology."},{"issue":"2","key":"5557_CR21","doi-asserted-by":"publisher","first-page":"e89072","DOI":"10.1371\/journal.pone.0089072","volume":"9","author":"Y Ingrasciotta","year":"2014","unstructured":"Ingrasciotta Y, Sultana J, Giorgianni F, Caputi AP, Arcoraci V, Tari DU, et al. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PLoS One. 2014;9(2):e89072.","journal-title":"PLoS One."},{"key":"5557_CR22","unstructured":"CDC;Pages. Accessed at U.S. Department of Health and Human Services at https:\/\/www.cdc.gov\/nchs\/tutorials\/NHANES\/NHANESAnalyses\/NHANES_Analyses_intro.htm on April 9 2019."},{"key":"5557_CR23","doi-asserted-by":"crossref","unstructured":"Norton EC, Dowd BE, Maciejewski ML. Marginal effects-quantifying the effect of changes in risk factors in logistic regression models. JAMA. 2019.","DOI":"10.1001\/jama.2019.1954"},{"issue":"2","key":"5557_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","volume":"70","author":"RL Wasserstein","year":"2016","unstructured":"Wasserstein RL, Lazar NA. The ASA\u2019s statement on p-values: context, process, and purpose. The American Statistician. 2016;70(2):129\u201333.","journal-title":"The American Statistician."},{"issue":"2","key":"5557_CR25","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics. 1979;6(2):65\u201370.","journal-title":"Scandinavian Journal of Statistics."},{"issue":"11","key":"5557_CR26","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.2215\/CJN.12311216","volume":"12","author":"M Zhan","year":"2017","unstructured":"Zhan M, St. Peter WL, Doerfler RM, Woods CM, Blumenthal JB, Diamantidis CJ, et al. Patterns of NSAIDs use and their association with other analgesic use in CKD. Clinical Journal of the American Society of Nephrology. 2017;12(11):1778\u201386.","journal-title":"Clinical Journal of the American Society of Nephrology."},{"issue":"12","key":"5557_CR27","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.amjmed.2008.06.035","volume":"121","author":"WC Winkelmayer","year":"2008","unstructured":"Winkelmayer WC, Waikar SS, Mogun H, Solomon DH. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med. 2008;121(12):1092\u20138.","journal-title":"Am J Med."},{"issue":"3","key":"5557_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.ajkd.2013.09.009","volume":"63","author":"A Farag","year":"2014","unstructured":"Farag A, Garg AX, Li L, Jain AK. Dosing errors in prescribed antibiotics for older persons with CKD: a retrospective time series analysis. Am J Kidney Dis. 2014;63(3):422\u20138.","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"5557_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/jamainternmed.2013.12963","volume":"174","author":"CL Tseng","year":"2014","unstructured":"Tseng CL, Soroka O, Maney M, Aron DC, Pogach LM. Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med. 2014;174(2):259\u201368.","journal-title":"JAMA Intern Med."},{"issue":"21","key":"5557_CR30","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","volume":"70","author":"X Yao","year":"2017","unstructured":"Yao X, Tangri N, Gersh BJ, Sangaralingham LR, Shah ND, Nath KA, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017;70(21):2621\u201332.","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"5557_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238\u201346.","journal-title":"JAMA Intern Med."},{"issue":"10","key":"5557_CR32","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1681\/ASN.2015121377","volume":"27","author":"Y Xie","year":"2016","unstructured":"Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153\u201363.","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"5557_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12882-016-0325-4","volume":"17","author":"P Arora","year":"2016","unstructured":"Arora P, Gupta A, Golzy M, Patel N, Carter RL, Jalal K, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol. 2016;17(1):112.","journal-title":"BMC Nephrol."},{"issue":"6","key":"5557_CR34","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.kint.2016.12.021","volume":"91","author":"Y Xie","year":"2017","unstructured":"Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91(6):1482\u201394.","journal-title":"Kidney Int."},{"issue":"10","key":"5557_CR35","doi-asserted-by":"publisher","first-page":"e0204231","DOI":"10.1371\/journal.pone.0204231","volume":"13","author":"A Rodriguez-Poncelas","year":"2018","unstructured":"Rodriguez-Poncelas A, Barcelo MA, Saez M, Coll-de-Tuero G. Duration and dosing of proton pump inhibitors associated with high incidence of chronic kidney disease in population-based cohort. PLoS One. 2018;13(10):e0204231.","journal-title":"PLoS One."},{"key":"5557_CR36","doi-asserted-by":"crossref","unstructured":"Qiu T, Zhou J, Zhang C. Acid-suppressive drugs and risk of kidney disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2018.","DOI":"10.1111\/jgh.14157"},{"issue":"3","key":"5557_CR37","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1053\/j.gastro.2017.05.046","volume":"153","author":"DCF Klatte","year":"2017","unstructured":"Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702\u201310.","journal-title":"Gastroenterology."},{"key":"5557_CR38","doi-asserted-by":"publisher","unstructured":"Davison SN. Clinical pharmacology considerations in pain management in patients with advanced kidney failure. Clinical Journal of the American Society of Nephrology. 2019:https:\/\/doi.org\/10.2215\/CJN.05180418.","DOI":"10.2215\/CJN.05180418"},{"issue":"5","key":"5557_CR39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jpainsymman.2004.02.021","volume":"28","author":"M Dean","year":"2004","unstructured":"Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497\u2013504.","journal-title":"J Pain Symptom Manage."},{"issue":"6","key":"5557_CR40","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2016.10924","volume":"316","author":"M Afkarian","year":"2016","unstructured":"Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988\u20132014. JAMA. 2016;316(6):602\u201310.","journal-title":"JAMA."},{"key":"5557_CR41","doi-asserted-by":"crossref","unstructured":"ADA. American Diabetes Association Standards of Medical Care in Diabetes\u20142019. Section 9. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2019;42(Supplement 1):S90\u2013S102.","DOI":"10.2337\/dc19-S009"},{"key":"5557_CR42","unstructured":"FDA 2016;Pages. Accessed at U.S. Food and Drug Administration at https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm493244.htm on February 21 2019."},{"issue":"8","key":"5557_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11892-018-1018-0","volume":"18","author":"R Silbert","year":"2018","unstructured":"Silbert R, Salcido-Montenegro A, Rodriguez-Gutierrez R, Katabi A, McCoy RG. Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies. Curr Diab Rep. 2018;18(8):53.","journal-title":"Curr Diab Rep."},{"issue":"10","key":"5557_CR44","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.2215\/CJN.04970512","volume":"7","author":"AW Williams","year":"2012","unstructured":"Williams AW, Dwyer AC, Eddy AA, Fink JC, Jaber BL, Linas SL, et al. Critical and honest conversations: the evidence behind the \u201cChoosing Wisely\u201d campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol. 2012;7(10):1664\u201372.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9","key":"5557_CR45","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/aje\/kwj331","volume":"164","author":"V Schneider","year":"2006","unstructured":"Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881\u20139.","journal-title":"Am J Epidemiol."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-019-05557-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-019-05557-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-019-05557-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T20:11:53Z","timestamp":1606853513000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-019-05557-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["5557"],"URL":"https:\/\/doi.org\/10.1007\/s11606-019-05557-8","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,2]]},"assertion":[{"value":"22 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors have no relevant conflicts of interest to declare. In the past 36 months, Dr. McCoy was also supported by the AARP\u00ae Quality Measure Innovation Grant through a collaboration with OptumLabs\u00ae and the NQF Measure Incubator. Dr. Jeffery has received research support through Mayo Clinic from the National Heart, Lung and Blood Institute (R56HL130496 and R21HL140287), the Agency for Healthcare Research and Quality (R01HS025164), the American Cancer Society (131611-RSGI-17-154-01-CPHPS), the Food and Drug Administration-funded Yale-Mayo CERSI (U01FD 05938), and the National Center for Advancing Translational Sciences (UL1TR 02377; U01TR 02743). In the past 36 months, Dr. Shah has received research support through Mayo Clinic from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938); the Centers of Medicare and Medicaid Innovation under the Transforming Clinical Practice Initiative (TCPI); the Agency for Healthcare Research and Quality (R01HS025164; R01HS025402; R03HS025517); the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R56HL130496; R01HL131535); the National Science Foundation; and the Patient Centered Outcomes Research Institute (PCORI) to develop a Clinical Data Research Network (LHSNet).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}